Why did GBT.PA stock drop sharply pre-market?

The pre-market fall to **€9.27** (-24.14%) followed the earnings release and renewed focus on Guerbet’s leverage, margin pressure and inventory levels. Heavy volume and oversold technicals amplified selling pressure.

What are the key valuation numbers for GBT.PA stock?

At **€9.27**, market cap is about **€116,812,373.00**, EPS **€0.61**, PE **15.20**, price-to-book **0.35**, and EV/EBITDA **5.37**, which point to a stressed valuation but potential recovery if fundamentals improve.

What is Meyka AI’s price forecast for GBT.PA stock?

Meyka AI's forecast model projects a 12-month price of **€18.13** and a quarterly projection of **€9.41**. These are model-based projections and not guarantees; they imply significant upside from today’s price if conditions normalize.

Should traders buy GBT.PA stock after the dip?

Buying depends on risk tolerance. The stock is oversold with high volatility and debt concerns. Consider scaled entries, tight stops and monitor earnings progress and leverage reduction before increasing exposure.

EU Stocks

Pre-market: GBT.PA stock down 24.14% to €9.27 on EURONEXT: watch outlook

ByHuzaifa Zahoor March 13, 2026

GBT.PA stock opened the pre-market session sharply lower after yesterday’s sell-off, trading at €9.27 (-24.14%) on EURONEXT with volume 96,834 shares. The drop follows an earnings update and renewed investor focus on leverage and margins in the Healthcare medical-devices space. We review the catalysts, valuation, technicals and short-term price targets to frame what traders should watch as the session begins in Europe.